P53, secreted by K-Ras-Snail pathway, is endocytosed by K-Ras-mutated cells; Implication of target-specific drug delivery and early diagnostic marker

Oncogene

Volumn 28, Issue 19, 2009, Pages 2005-2014

  Lee, S H ^a   Lee, S J ^a   Chung, J Y ^a   Jung, Y S ^a   Choi, S Y ^a   Hwang, S H ^b   Choi, D ^c   Ha, N C ^a   Park, B J ^a  

^a Pusan National University   (South Korea)

^b Pusan National University Hospital   (South Korea)

^c Internal Medicine   (South Korea)

Author keywords

Diagnostic marker; Endocytosis; P53; Snail; secretion

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIBODY; K RAS PROTEIN; PROTEASOME; PROTEIN P53; PROTEINASE; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; RAS PROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ARTICLE; CELL MUTANT; COLON CANCER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EARLY DIAGNOSIS; ENDOCYTOSIS; HUMAN; HUMAN CELL; LUNG CANCER; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TUMOR SUPPRESSOR GENE; GENETICS; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; TRANSPORT VESICLE;

GASTROPODA;

AUTOANTIBODIES; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSPORT VESICLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 66149120694     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.67     Document Type: Article

References (30)

1. Bergqvist M, Brattstrom D, Larsson A, Hesselius P, Brodin O, Wagenius G. (2004). The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival. BMC Cancer 4: 66.
2. Bres V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Treand C et al. (2003). A non-proteolytic role for ubiquitin in Tatmediated transactivation of the HIV-1 promoter. Nat Cell Biol 5: 754-761.
3. Collins NL, Reginato MJ, Paulus JK, Sgroi DC, Labaer J, Brugge JS. (2005). G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol 25: 5282-5291.
4. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
5. Genschel J, Schmidt HH. (2000). Mutations in the LMNA gene encoding lamin A/C. Hum Mutat 16: 451-459.
6. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL. (2005). The nuclear lamina comes of age. Nat Rev Mol Cell Biol 6: 21-31.
7. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M et al. (2003). Tumor induction by an endogenous K-Ras oncogene is highly dependent on cellular context. Cancer Cell 4: 111-120.
8. Halaschek-Weiner J, Wacheck V, Kloog Y, Jansen B. (2004). Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2; two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal 16: 1319-1327.
9. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. (2006). Cancer statistics, 2006. CA Cancer J Clin 56: 106-130.
10. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
11. Kajita M, McClinic KN, Wade PA. (2004). Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 24: 7559-7566.
12. Koivusalo R, Mialon A, Pitkänen H, Westermarck J, Hietanen S. (2006). Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists. Cancer Res 66: 11817-11824.
13. Le PU, Nabi IR. (2003). Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J Cell Sci 116: 1059-1071.
14. Lee SH, Lee SJ, Jung YS, Xu YB, Kang HS, Ha NC et al. (2009). Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia 11: 22-31.
15. Leon M, Kew MC. (1995). Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res 15: 859-861.
16. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C et al. (1991). Multiple K-Ras codon 12 mutations in cholangio-carcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 51: 3497-3502.
17. Limpaiboon T, Sripa B, Wongkham S, Bhudhisawasdi V, Chau-in S, Teerajetgul Y. (2004). Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma. Hepatogastroenterology 51: 25-28.
18. Nie L, Sasaki M, Maki CG. (2007). Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 282: 14616-14625.
19. Park BJ, Oh YS, Park SY, Choi SJ, Rudolph C, Schlegelberger B et al. (2006). AIMP3 haploinsufficiency disrupts oncogene-induced p53 activation and genomic stability. Cancer Res 66: 6913-6918.
20. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN et al. (2007). Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell 128: 931-946.
21. Rieder CL, Maiato H. (2004). Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 7: 637-651.
22. Roy UK, Rial NS, Kachel KL, Gerner EW. (2008). Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol Carcinog 47: 538-553.
23. Shin J, Kim J, Ryu B, Chi SG, Park H. (2006). Caveolin-1 is associated with VCAM-1 dependent adhesion of gastric cancer cells to endothelial cells. Cell Physiol Biochem 17: 211-220.
24. Soussi T. (2000). p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788.
25. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD et al. (2000). Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 275: 11327-11332.
26. Tsuda H, Satarug S, Bhudhisawasdi V, Kihana T, Sugimura T, Hirohashi S. (1992). Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog 6: 266-269.
27. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S et al. (2004). Endogenous oncogenic K-RasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375-387.
28. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
29. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
30. Yang GY, Wagner TD, Fuss M, Thomas Jr CR. (2005). Multimodality approaches for pancreatic cancer. CA Cancer J Clin 55: 352-367.